Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02182986 · ClinicalTrials.gov registry record
Biomarkers for Post-Transplant Lymphoproliferative Disorders in Children
A clinical trial, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 944
- Enrollment target
NCT02182986: Completed study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT02182986 is a clinical trial that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 944 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02182986 has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 944 participants
- Enrollment target
Study Summary
Solid organ transplantation is an important therapeutic option for children with a variety of end stage diseases. However, the same immunosuppressive medications that are required to prevent the child's immune system from attacking and rejecting the transplanted organ can predispose these individuals to developing a very serious cancer that is linked to Epstein-Barr virus (EBV).
Primary Outcome
The development of EBV positive PTLD during the study period as assessed by the local site pathologist, with confirmation of the PTLD diagnosis by the Study Clinicopathological Review Board (SCPRB)
Interventions
- PROCEDURE transplant
- DRUG Immunosuppressive Drugs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 944 participants |
| Start Date | 2014-08-14 |
| Est. Completion | 2019-05-15 |
What the finished NCT02182986 record still lists
NCT02182986 is an observational study that tracks outcomes without assigning an intervention. The registered 944 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which transplant is the first listed.
NCT02182986 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02182986 about?
NCT02182986 is a clinical study titled "Biomarkers for Post-Transplant Lymphoproliferative Disorders in Children". Solid organ transplantation is an important therapeutic option for children with a variety of end stage diseases. However, the same immunosuppressive medications that are required to prevent the child's immune system from attacking and rejecting the transplanted organ can predispose these individual...
What is the current status of trial NCT02182986?
This trial is currently completed. The enrollment target is 944 participants. The study started on 2014-08-14. Estimated completion is 2019-05-15.
What interventions are being tested in trial NCT02182986?
The interventions under investigation include: transplant (PROCEDURE), Immunosuppressive Drugs (DRUG).
Who is sponsoring clinical trial NCT02182986?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05020236 · 944 participants · Phase 3
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- NCT06808334 · 942 participants
CLAiR Pivotal Study
- NCT07190209 · 942 participants · Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- NCT07190222 · 942 participants · Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI